Nanoparticles with mRNA target lung cancer and muscle wasting at once

Researchers at Oregon State University developed lipid nanoparticles carrying follistatin mRNA that are delivered intravenously to lung tumors. In mice, the therapy cut tumor burden about 2.5-fold while also supporting muscle growth in cancer cachexia. The study is published in the Journal of Controlled Release; human trials have not yet begun.

• Nanoparticles accumulate in lung tumors instead of the liver, unlike conventional LNPs
• Tumor burden in mice fell roughly 2.5-fold
• Follistatin mRNA suppresses tumors and supports muscle growth
• Cachexia kills up to 30% of cancer patients it affects